Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Mar 30 2022 | Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program Industry News In The News Industry Read More Mar 28 2022 | Volunteer for Committee and Leadership Positions for the 2022-2024 Term HFSA News HFSA Committees Read More Mar 27 2022 | HFSA President's Message: March 2022 HFSA News President's Updates Read More Mar 16 2022 | Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Industry News In The News Industry Read More Mar 14 2022 | New Episode of the Heart Failure Beat Explores Guideline-Directed Medical Therapy in HF – Evidence vs. Practicality HFSA News Podcasts Provider Education Read More Pagination First page « First Previous page ‹ Previous … Page 66 Page 67 Page 68 Page 69 Current page 70 Page 71 Page 72 Page 73 Page 74 … Next page Next › Last page Last »
Mar 30 2022 | Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program Industry News In The News Industry Read More
Mar 28 2022 | Volunteer for Committee and Leadership Positions for the 2022-2024 Term HFSA News HFSA Committees Read More
Mar 16 2022 | Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease Industry News In The News Industry Read More
Mar 14 2022 | New Episode of the Heart Failure Beat Explores Guideline-Directed Medical Therapy in HF – Evidence vs. Practicality HFSA News Podcasts Provider Education Read More
